Raising market visibility for a biotech company
Novadip shares positive 12-month results from phase 1b/2a trial with NVDX3 in trauma
No copyright
BiocSol secures additional €4.4M to develop its sustainable crop protection solutions
© David Plas
Novadip reports 12-month results from phase 1b/2a trial of NVD003 to treat rare pediatric disease Congenital Pseudarthrosis of the Tibia
© Novadip
BiocSol
Raising market visibility for an agritech company
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy
No copyright
Novadip appoints Drew Trivisonno to the board of directors to drive financial and business development
No copyright
BiPER Therapeutics raises €800,000 in bridge funding to advance its first-in-class BiP-Inhibitor for gastrointestinal cancers to clinical trials
©No copyright
Orikine Bio secures €800k in innovation research funding to advance groundbreaking autoimmune disease therapy
©No copyright
Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion
© Novadip